CADTH Canadian Drug Expert Committee recommendation: Travoprost 0.003% (Izba -- Novartis Pharmaceuticals Canada inc. on behalf of Alcon Canada Inc.) : indication : for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension

The CADTH Canadian Drug Expert Committee (CDEC) recommends that travoprost 0.003% preserved with polyquaternium-1 (PQ) be reimbursed for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT), if the following condition is met: Th...

Full description

Corporate Authors: CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2017, October 2017
Edition:Version: 1.0
Series:CADTH common drug review
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Summary:The CADTH Canadian Drug Expert Committee (CDEC) recommends that travoprost 0.003% preserved with polyquaternium-1 (PQ) be reimbursed for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT), if the following condition is met: The drug plan cost of treatment with travoprost 0.003% PQ should not exceed the drug plan cost of treatment with the least costly alternative prostaglandin analogue (PGA)
Item Description:"Final."
Physical Description:1 PDF file (5 pages)